Cartesian Therapeutics (RNAC) Earnings Date, Estimates & Call Transcripts $10.53 -0.01 (-0.09%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$10.52 -0.01 (-0.14%) As of 08/8/2025 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Cartesian Therapeutics Earnings Summary Cartesian Therapeutics posted Q2 2025 earnings on August 7, 2025, reporting an EPS of $0.50, which topped the consensus estimate of -$0.76 by $1.26. Quarterly revenue was reported to be $0.30 million, below analysts' expectations of $0.77 million. With a trailing EPS of -$52.83, Cartesian Therapeutics' earnings are expected to decrease next year, from $4.56 to ($3.07) per share. Q2 2025 Earnings ResourcesQ2 2025 Earnings ReportSEC FilingLatest Q2 2025 Earnings DateAug. 7EstimatedConsensus EPS (Aug. 7) -$0.76 Actual EPS (Aug. 7) $0.50 Beat By $1.26 Actual Revenue (Aug. 7) $0.30M Get Cartesian Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cartesian Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataRNAC Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.RNAC Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Cartesian Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.47-$0.47-$0.47Q2 20252-$0.74-$0.68-$0.71Q3 20252-$0.73-$0.52-$0.63Q4 20252-$0.58-$0.54-$0.56 FY 2025 7 -$2.52 -$2.21 -$2.37 Q1 20262-$0.80-$0.54-$0.67Q2 20262-$0.94-$0.55-$0.75Q3 20262-$1.10-$0.56-$0.83Q4 20262-$1.22-$0.51-$0.87 Cartesian Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025-$0.76$0.50+$1.26$0.50$0.77M$0.30M5/8/2025Q1 2025-$0.61-$0.68 -$0.07-$0.68$0.69M$1.10M8/8/2024--$0.81$0.54+$1.35$0.54$6.00M$33.45M5/8/2024Q1 2024-$0.81-$1.97 -$1.16$6.56-$5.84M3/7/2024Q4 2023-$0.30-$2.40 -$2.10$1.23-$8.27M11/13/2023Q3 2023-$1.05-$1.20 -$0.15-$0.10$9.70M$6.55M8/17/2023Q2 2023-$1.35-$1.05+$0.30-$0.07$9.90M$5.25M Cartesian Therapeutics Earnings - Frequently Asked Questions When did Cartesian Therapeutics announce their last quarterly earnings? Cartesian Therapeutics (NASDAQ:RNAC) last announced its quarterly earning data on Thursday, August 7, 2025. Learn more on RNAC's earnings history. Did Cartesian Therapeutics beat their earnings estimates last quarter? In the previous quarter, Cartesian Therapeutics (NASDAQ:RNAC) reported $0.50 earnings per share (EPS) to beat the analysts' consensus estimate of ($0.76) by $1.26. Learn more on analysts' earnings estimate vs. RNAC's actual earnings. How can I view Cartesian Therapeutics' earnings report? Cartesian Therapeutics' earnings report can be found in their filing with the SEC. View SEC filing How much revenue does Cartesian Therapeutics generate each year? Cartesian Therapeutics (NASDAQ:RNAC) has a recorded annual revenue of $34.17 million. How much profit does Cartesian Therapeutics generate each year? Cartesian Therapeutics (NASDAQ:RNAC) has a recorded net income of -$77.42 million. RNAC has generated -$52.83 earnings per share over the last four quarters. What is Cartesian Therapeutics' EPS forecast for next year? Cartesian Therapeutics' earnings are expected to decrease from $4.56 per share to ($3.07) per share in the next year. More Earnings Resources from MarketBeat Related Companies BHVN Earnings Date COGT Earnings Date TVTX Earnings Date HROW Earnings Date WVE Earnings Date CDTX Earnings Date CVAC Earnings Date AUPH Earnings Date PRAX Earnings Date CALT Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Airbnb Beats Earnings, But the Growth Story Is Losing AltitudeDutch Bros Just Flipped the Script With a Massive Earnings BeatIs Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?Constellation Energy’s Earnings Beat Signals a New EraRealty Income Rallies Post-Earnings Miss—Here’s What Drove ItDon't Mix the Signal for Noise in Super Micro Computer's EarningsWhy Monolithic Power's Earnings and Guidance Ignited a Rally This page (NASDAQ:RNAC) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNAC Stock Alerts